In this context, cohort E of the phase II/III B-FAST trial (NCT03178552) is designed to evaluate the efficacy and safety of a combination treatment with atezolizumab, vemurafenib, and cobimetinib in patients with advanced NSCLC harboring BRAF V600 mutations. Here, BRAF is linked to non-small cell lung carcinoma.